OBJECTIVE Long treatment periods, repeated hospitalizations and side effects of chemotherapy besides the knowledge of having cancer may all affect the psyche of these patients. In this study, we ...investigated the effects of illness perception on anxiety and depression in cancer patients receiving chemotherapy treatment. METHODS A total of 182 patients were recruited in this cross-sectional study. Hospital Anxiety Depression Scale, Visual Analoge Scale and Brief Illness Perception Questionnaire were used to assess the anxiety and depression, pain and illness perception, respectively. RESULTS There were 103 (56.59%) female and 79 (43.41%) male patients in this study. The present sample had possible clinical levels of anxiety and depression of 25.3% and 26.4%, respectively, and probable clinical levels of anxiety and depression of 25.8% for both. Positive illness perception parameters, such as personal control and treatment control, were both not correlated with anxiety scores (p=0.120, p=0.070, respectively). According to the evaluation of depression scores, personel control was negatively correlated (p<0.005) and no relation was found to treatment control (p=0.062). VAS was positively correlated with negative illness perception (p<0.005). CONCLUSION Anxiety and depression were strongly associated with illness perception and pain in cancerpatients during chemotherapy treatment. Oncologists and chemotherapy nurses should pay more attentive to the signs and symptoms of anxiety and depression, and offer specific supportive therapy to each patient.
OBJECTIVE Brain metastasis develops in one-third of the patients with adult cancer and it causes significant morbidity and mortality on the patients. In this study, we aimed to show the prognostic ...effects of temporal muscle thickness and inflammatory (neutrophil-lymphocyte ratio, platelet-lymphocyte ratio and systemic inflammation response index) and prognostic nutritional index on survival in lung cancer patients with brain metastasis. METHODS In this study, a total of 94 cancer patients diagnosed with brain metastasis lung cancer were evaluated retrospectively. Routine blood sampling was tested within 10 days of brain MR imaging before the use of steroid therapy. RESULTS Temporal muscle thickness was significantly associated with overall survival, according to cut-off 4.32 (95% CI 0.66-0.99; p=0.040). The risk of death increased by 18.8%, with every millimeter reduction in temporal muscle thickness. Neutrophil-lymphocyte ratio, systemic inflammation response index and prognostic nutritional index were associated with overall survival (p=0.002, p=0.008, p=0.001, respectively). CONCLUSION The findings showed that the use of temporal muscle thickness and inflammatory-nutritional parameters for the evaluation of sarcopenia were practical and rapid methods. In this group of patients with a short duration of survival, the prognosis of patients can be predicted, and their exposure to toxic treatment may be prevented by the evaluation of sarcopenia.
The present study aims to evaluate the antioxidant effect of beta-glucan on oxidative DNA damage by comet assay.
A total of 19 adult females and males diagnosed with stage 3-4 colorectal cancer and a ...control group of 20 age-matched healthy subjects were enrolled in the study. Blood samples of the participants were analyzed using Comet Assay for the parameters of DNA damage.
Significantly increased DNA damage was observed in patients versus the control group as indicated by greater values of tail moment, tail percent DNA and tail length. Following incubation with β-glucan, a substantial reduction was found in the aforementioned parameters of DNA damage. Comet assay revealed significant levels of endogenous DNA damage in patients as shown by remarkable increases in the tail moment, the percentage of DNA in the tail and the tail length values, in comparison with the control group. Following treatment of fresh whole blood with β-glucan incubation, DNA damages were significantly reduced, but lower values were observed after β-glucan incubation in the patient group versus control group.
β-Glucan was found to reduce DNA damage substantially in colorectal cancer patients and show antimutagenic effects. Our results suggested that dietary β-glucan intake might be important in the genesis of colorectal cancer tumors.
Purpose
We compared the ability of
68
Ga-FAPI PET//CT with
18
FDG PET/CT imaging techniques to detect additional lesions in breast cancer patients that may affect further chemotherapy options.
...Methods
A total of 48 patients with breast cancer underwent concurrent
68
Ga-FAPI-04 and
18
FDG PET/CT regardless of whether they had received chemotherapy or not in the last month before imaging. Both modalities were compared according to various parameters: clinical/pathological features, number of lesions detected, activity uptake (SUV
max
), and the effect on the evaluation of response to treatment in the post-chemotherapy group.
Results
This retrospective study included 48 patients with breast cancer (mean age 53.3 ± 11.7 years; IDC 89.6%; ILC 10.4%). In the comparison of both modalities, no statistical significance was obtained in terms of the pathological characteristics of the patients. More lesions were demonstrated in all categorized regions in
68
Ga-FAPI PET/CT imaging with higher uptake values compared to
18
FDG PET/CT in this study. In the treatment response evaluation of the post-chemotherapy group, 12 cases (12/24) who were evaluated as PMR, CMR, or SD according to
18
FDG PET/CT results were later accepted as PD due to newly detected lesions in complementary
68
Ga-FAPI PET/CT imaging and treatment of patients was managed accordingly by clinicians.
Conclusion
It was determined that
68
Ga-FAPI PET/CT was superior to
18
FDG PET/CT in terms of accuracy and it was thought that
68
Ga-FAPI PET/CT could be utilized as an additional complementary imaging to
18
FDG PET/CT. Moreover,
68
Ga-FAPI PET/CT, with its significant theranostic potential, could become a key element in predicting the pathological response of breast cancer patients in further researches.
The optimal treatment for metastatic colorectal cancer (mCRC) after the second line is still controversial. Regorafenib has been the standard of care in this setting as it improved overall survival ...(OS) compared to placebo. In real-world practice chemotherapy rechallenge is also a preferred option even though supporting evidence is not enough. We aim to compare the efficacy of regorafenib and 5-fluorouracil-based (5-FU) rechallenge treatment in the third line setting of mCRC.
In this retrospective multi-institutional trial, mCRC patients from 21 oncology centers who progressed after 2 lines of chemotherapy were analyzed. Patients who were treated with regorafenib or rechallenge therapy in the third-line setting were eligible. Rechallenge chemotherapy was identified as the re-use of the 5-FU based regimen which was administered in one of the previous treatment lines. OS, disease control rate (DCR), progression free survival (PFS) and toxicity were analyzed.
Three hundred ninety-four mCRC patients were included in the study. 128 (32.5%) were in the rechallenge, and 266 (67.5%) were in the regorafenib group. Median PFS was 5.82 months in rechallenge and 4 months in regorafenib arms (hazard ratio:1.45,95% CI, p = 0.167). DCR was higher in the rechallenge group than regorafenib (77% vs 49.5%, respectively, p = < 0.001). Median OS after the third-line treatment was 11.99 (95% CI, 9.49-14.49) and 8.08 months (95% CI, 6.88-9.29) for rechallenge and regorafenib groups, respectively (hazard ratio:1.51, 95% CI, p < 0.001). More adverse effects and discontinuation were seen with regorafenib treatment.
Our study revealed that higher disease control and OS rates were achieved with rechallenge treatment compared to regorafenib, especially in patients who achieved disease control in one of the first two lines of therapy.
Celotno besedilo
Dostopno za:
DOBA, IZUM, KILJ, NUK, PILJ, PNG, SAZU, SIK, UILJ, UKNU, UL, UM, UPUK
The aim of this study is to determine the effect of breathing exercise on nausea, vomiting, and functional status in breast cancer patients undergoing chemotherapy.
This randomized controlled trial ...was conducted with a total of 60 breast cancer patients in the ambulatory chemotherapy unit of a university hospital. The data were collected using Patient Information Form, Functional Living Index-Cancer (FLI-C), Visual Analog Scale, and Patient Diary. The patients were followed up for the first seven days. While the control group received routine nursing care until the posttest, the intervention group received breathing exercise for six days. On the seventh day, FLI-C was repeated for all the patients.
It was determined that the patients in the intervention group had less number of nausea, vomiting, and retching episodes after the breathing exercise (p < 0.05) and experienced lower severity of nausea (p < 0.05) compared to patients in the control group.
Consequently, it was determined that the breathing exercise reduced chemotherapy-induced nausea, vomiting and retching in breast cancer patients and affected positively functional status of patients.
•In breast cancer patients undergoing chemotherapy, nausea-vomiting is frequently common and affects functional status of patients negatively.•Patients with breast cancer seek complementary and alternative therapies to reduce nausea and vomiting and to improve their functional status.•Breathing exercises are important in alleviating chemotherapy-induced nausea and vomiting in patients with breast cancer.
Objective: Sorafenib has limited survival benefits with lower tumor response rates in hepatocellular carcinoma (HCC). Many researchers have attempted to identify predictors for sorafenib. In this ...study, we compared the role of lymphocyte/monocyte ratio (LMR), neutrophil/monocyte ratio (NMR), platelet/neutrophil ratio (PNR), systemic inflammation response index (SIRI) and systemic immune inflammation (SII) in patients with HCC received sorafenib treatment. Materials and Methods: In this study, we retrospectively enrolled 80 patients who used Sorafenib in advanced stage HCC between January 2011 and December 2018. Baseline neutrophil, lymphocyte, monocyte and platelet counts were recorded. Cut-off points of LMR, NMR, PNR, SIRI and SII were calculated by the receiver operating characteristic (ROC) curve analysis. Overall survival (OS) and progression-free survival (PFS) were demonstrated by Kaplan-Meier analysis, and the log-rank test was used for comparing the curves Results: Median OS was 29 weeks (95% CI 20.41-37.58), and PFS was 16 weeks (95% CI: 12.04-19.95). We found that only low SIRI value was associated with increased survival. OS were 19 weeks for SIRI =2.2 and 38 weeks (95% CI: 30.96-45.03 for patients with SIRI <2.2 (p=0.005). PFS was 12 weeks for SIRI =2.2 and 20 weeks for SIRI <2.2 (p=0.098). The life expectancy of patients with SIRI values less than 2.2 was 2.02 times higher than the other group. Conclusion: To our knowledge, NMR and PNR indexes were evaluated for the first time in our study in HCC patients. Low SIRI value was related to increased survival in patients receiving sorafenib with HCC. Keywords: Hepatocellular carcinoma, inflammation, sorafenib
Introduction: Bone marrow involvement (BoMI) may be common during the tumour’s lifespan or, sometimes, it may be the first sign of manifestation of a disease. Prostate cancer at an extensive stage ...has osteoblastic bone metastasis. The purpose of this study is to explore the results of prostate cancer with BoMI that is diagnosed by bone marrow biopsy. Methods: We retrospectively evaluated 55 patients with BoMI of solid tumours and 8 patients with histopathologically proven BoMI of prostate cancer. The overall survival (OS) was demonstrated by Kaplan–Meier analysis, and the curves were compared by the log-rank test. Results: The median age of patients was 67.5 years (range: 46-83 years). Bone was the most common site of metastasis, except BoMI (n=8, 100%). At the time of diagnosis of BoMI, the most abnormal haematological findings were anaemia (87.5%) and thrombocytopenia (87.5%), followed by leucopenia (37.5%). The median time of BoMI was 16.8 months (range: 0-57.8). The median and mean OS after the diagnosis of BoMI were 38 days 95% confidence interval (CI); 0-175.2 and 143 days (95% CI; 27.7-259.9), respectively. According to the treatment status after BoMI, median OS were 215 days for patients who underwent oncologic treatment and 21 days in patients followed up with best supportive care (BSC) (p=0.014). Conclusion: BoMI in prostate cancer and other solid tumours remain a dismal situation. According to survival difference between the patients who received treatment and BSC after BoMI diagnosis, patients who are eligible for oncologic treatment should be encouraged for continuing the treatment.
Cancer was a common noncommunicable disease in Syria before the present conflict and is now a major disease burden among 3.6 million Syrian refugees in Turkey. Data to inform health care practice are ...needed.
To explore sociodemographic characteristics, clinical characteristics, and treatment outcomes of Syrian patients with cancer residing in the southern border provinces of Turkey hosting more than 50% of refugees.
This was a retrospective hospital-based cross-sectional study. The study sample consisted of all adult and children Syrian refugees diagnosed and/or treated for cancer between January 1, 2011, and December 31, 2020, in hematology-oncology departments of 8 university hospitals in the Southern province of Turkey. Data were analyzed from May 1, 2022, to September 30, 2022.
Demographic characteristics (date of birth, sex, and residence), date of first cancer-related symptom, date and place of diagnosis, disease status at first presentation, treatment modalities, date and status at last hospital visit, and date of death. The International Statistical Classification of Diseases and Related Health Problems, Tenth Revision and International Classification of Childhood Cancers, Third Edition, were used for the classification of cancer. The Surveillance, Epidemiology, and End Results system was applied for staging. The diagnostic interval was defined as the number of days from first symptoms until the diagnosis. Treatment abandonment was documented if the patient did not attend the clinic within 4 weeks of a prescribed appointment throughout the treatment.
A total of 1114 Syrian adult and 421 Syrian children with cancer were included. The median age at diagnosis was 48.2 (IQR, 34.2-59.4) years for adults and 5.7 (IQR, 3.1-10.7) years for children. The median diagnostic interval was 66 (IQR, 26.5-114.3) days for adults and 28 (IQR, 14.0-69.0) days for children. Breast cancer (154 13.8%), leukemia and multiple myeloma (147 13.2%), and lymphoma (141 12.7%) were common among adults, and leukemias (180 42.8%), lymphomas (66 15.7%), and central nervous system neoplasms (40 9.5%) were common among children. The median follow-up time was 37.5 (IQR, 32.6-42.3) months for adults and 25.4 (IQR, 20.9-29.9) months for children. The 5-year survival rate was 17.5% in adults and 29.7% in children.
Despite universal health coverage and investment in the health care system, low survival rates were reported in this study for both adults and children with cancer. These findings suggest that cancer care in refugees requires novel planning within national cancer control programs with global cooperation.
PDF
